EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Targeting the ubiquitin–proteasome system and drug therapy in colorectal cancer

Ruixin Su, Yingying Shao, Qian Wang, Donghui Liu, Yitong Wang, Dexin Kong, Yuling Qiu

Journal of Molecular Cell Biology · 2026

DOI: 10.1093/jmcb/mjaf027 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Molecular Cell Biology, 2026. Verfasst von Ruixin Su und 6 weiteren Autor:innen. Beteiligte Einrichtung: Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University,…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Proteasome Endopeptidase Complex, Ubiquitin, Antineoplastic Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 119 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, China Postdoctoral Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Colorectal cancer (CRC) is the third most prevalent malignancy worldwide and the second leading cause of cancer-associated deaths, posing a significant threat to human health. Given the limited therapeutic options and poor prognosis associated with CRC, there is an urgent need to develop new targeted therapeutic strategies to enhance clinical outcomes. The ubiquitin–proteasome system (UPS), a central regulator for cellular protein homeostasis, plays a pivotal role in the initiation and progression of CRC. The UPS modulates several essential signaling pathways and is involved in regulating tumor immunity and resistance to chemotherapy. Thus, the UPS contributes significantly to the complex biological processes underlying CRC pathogenesis. In recent years, small-molecule compounds targeting the UPS have exhibited considerable therapeutic potential in CRC treatment. These drugs intervene in crucial steps in the UPS, such as the activity of E1, E2, and E3 enzymes, or directly target the proteasome, thereby regulating the degradation of oncogenic proteins and effectively impeding tumor progression. Moreover, emerging therapeutic strategies such as proteolysis-targeting chimera (PROTAC) and molecular glue technologies selectively degrade specific oncogenic proteins, thereby offering new avenues and promising opportunities for CRC treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsProteasome Endopeptidase ComplexUbiquitinAntineoplastic AgentsHumansAnimalsProteolysisMolecular Targeted TherapySignal Transduction

Stichwörter der Autor:innen

colorectal cancer (CRC)drug therapymolecular glueproteolysis-targeting chimera (PROTAC)ubiquitin–proteasome system (UPS)

Substanzen

Proteasome Endopeptidase ComplexUbiquitinAntineoplastic Agents

Autor:innen und Institutionen

  • Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin 300070, China.
  • School of Medicine, Nankai University, Tianjin 300071, China.
  • National Key Laboratory of Chinese Medicine Modernization, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.

Förderung

  • National Natural Science Foundation of China
  • China Postdoctoral Science Foundation

Zitieren

APA

Su, R., Shao, Y., Wang, Q., Liu, D., Wang, Y., Kong, D., & Qiu, Y. (2026). Targeting the ubiquitin–proteasome system and drug therapy in colorectal cancer. Journal of Molecular Cell Biology. https://doi.org/10.1093/jmcb/mjaf027

Vancouver

Su R, Shao Y, Wang Q, Liu D, Wang Y, Kong D, et al. Targeting the ubiquitin–proteasome system and drug therapy in colorectal cancer. Journal of Molecular Cell Biology. 2026. doi:10.1093/jmcb/mjaf027

BibTeX
@article{Su2026,
  author = {Su, Ruixin and Shao, Yingying and Wang, Qian and Liu, Donghui and Wang, Yitong and Kong, Dexin and Qiu, Yuling},
  title = {Targeting the ubiquitin–proteasome system and drug therapy in colorectal cancer},
  journal = {Journal of Molecular Cell Biology},
  year = {2026},
  doi = {10.1093/jmcb/mjaf027}
}
Kostenlos starten →